Insmed has decided to initiate the Phase III enabling trial based on promising results from an ongoing open-label, dose-escalation trial of Iplex in myotonic muscular dystrophy (MMD). To date, up to 70% of patients have reported improvements in one or more of several symptoms commonly associated with MMD.
Geoffrey Allan, Insmed’s president and CEO, said: “We are delighted to have a well-respected organization such as the Muscular Dystrophy Association (MDA) take an active role in the development of Iplex for this important indication. We believe third party commitments such as this clearly demonstrate the significance of our results to date and the validity of this approach to treat patients with this severely debilitating disease.”